Kontigo Care AB (KONT) AI Stock Analysis

• Market Cap: kr69.09M
• Dividend Yield: N/A
• Average Volume (3M): 48.70K
• Price to Earnings (P/E): 328.8
• Beta (1Y): 0.14
• Revenue Growth: -1.24%
• EPS Growth: -168.20%
• Country: SE
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.04
• Shares Outstanding: 35,251,427
• 10 Day Avg. Volume: 33,875
• 30 Day Avg. Volume: 48,701
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr1.98
• Price Target Upside: 0.94% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 46 Neutral
• Price Target: kr2.00 ▲(2.04% Upside)

Kontigo Care AB's overall stock score is primarily impacted by financial performance challenges, including negative revenue growth and cash flow issues. Technical analysis indicates bearish momentum, and valuation metrics are unattractive with a negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.

Kontigo Care AB Business Overview & Revenue Model

Company Description

Kontigo Care AB (KONT) is a Swedish company operating in the healthcare technology sector. The company specializes in developing digital solutions aimed at improving the treatment and rehabilitation processes for individuals with addiction issues. Its flagship product, Previct, is an eHealth platform that combines mobile technology, data analytics, and artificial intelligence to offer real-time monitoring and support for patients undergoing addiction treatment.

How the Company Makes Money

Kontigo Care AB generates revenue primarily through the sale and licensing of its digital health platform, Previct, to healthcare providers and institutions. The company offers its solutions on a subscription basis, which includes access to the platform, continuous updates, and customer support. Additionally, Kontigo Care collaborates with healthcare organizations and partners to further integrate its technology into existing treatment programs, enhancing its market reach and revenue potential. Significant factors contributing to its earnings include the increasing demand for innovative addiction treatment solutions and the growing adoption of digital health technologies in the healthcare industry.

Kontigo Care AB Financial Statement Overview

Summary

Kontigo Care AB exhibits a stable financial position with a strong balance sheet characterized by low leverage and high equity. While the company shows operational profitability, the income statement and cash flow metrics suggest areas for improvement in revenue growth and liquidity management.

Income Statement

Kontigo Care AB has demonstrated reasonable growth and stability in its income statement with a recent TTM revenue of 29.7M and improved metrics such as a gross profit margin of 100.45% and a net profit margin of 0.39%. However, the revenue growth rate has seen a slight decline of -1.73% from the previous annual period. The EBIT and EBITDA margins show healthy positions at 0.38% and 16.23% respectively, indicating profitable operations despite fluctuations in revenue growth.

Balance Sheet

The balance sheet of Kontigo Care AB reflects a strong equity position with an equity ratio of 80.47%. The debt-to-equity ratio is low at 0.06, suggesting low leverage and reduced financial risk. Return on equity stands at 0.23%, which is modest and showcases room for improvement in profitability from existing equity.

Cash Flow

The cash flow statement indicates challenges with negative free cash flow of -3.62M in the TTM period, reflecting potential liquidity constraints. However, the operating cash flow to net income ratio is robust at 30.64, indicating efficient cash generation from operations relative to net income. Free cash flow to net income ratio remains negative, highlighting concerns in covering capital expenditures from generated profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	29.28M	30.24M	28.95M	28.43M	24.54M	20.38M
Gross Profit	38.57M	40.08M	43.73M	28.24M	24.16M	20.01M
EBITDA	3.54M	5.07M	1.79M	4.13M	2.67M	2.20M
Net Income	-1.71M	775.00K	212.00K	2.90M	-1.20M	-1.28M
Balance Sheet
Total Assets	63.61M	67.74M	49.77M	31.39M	29.20M	24.46M
Cash, Cash Equivalents and Short-Term Investments	16.23M	21.86M	9.85M	5.74M	8.48M	4.94M
Total Debt	2.39M	3.67M	5.95M	0.00	1.08K	539.82K
Total Liabilities	13.01M	15.42M	19.05M	9.98M	10.74M	9.07M
Stockholders Equity	50.60M	52.32M	30.72M	21.40M	18.46M	15.40M
Cash Flow
Free Cash Flow	-641.00K	-5.61M	-9.07M	-2.20M	272.26K	248.43K
Operating Cash Flow	4.38M	4.61M	5.97M	7.30M	4.61M	3.99M
Investing Cash Flow	-9.99M	-10.70M	-16.73M	-9.50M	-4.34M	-3.74M
Financing Cash Flow	7.57M	18.11M	14.87M	-540.00K	3.27M	-987.76K

Kontigo Care AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.96
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:KONT, the sentiment is Negative. The current price of 1.96 is below the 20-day moving average (MA) of 2.03, below the 50-day MA of 2.09, and below the 200-day MA of 2.30, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 45.54 is Neutral, neither overbought nor oversold. The STOCH value of 10.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:KONT.

Kontigo Care AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PTRK	54 Neutral	297.57M	-4.01	-35.33%	―	-5.40%	-320.49%
KONT	46 Neutral	kr69.09M	328.79	-3.79%	―	-1.24%	-168.20%
ONCOZ	41 Neutral	79.68M	-10.82	0.00%	―	0.00%	42.09%
HEART	34 Underperform	97.97M	-1.18	0.00%	―	0.00%	0.00%
AINO	29 Underperform	49.51M	-7.76	0.00%	―	9.87%	67.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%